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Radiocurability of human tumours depends on many tumour- and
host-related factors. Among tumour-related factors, intrinsic
radiosensitivity is believed to be one of the most important and
relatively independent determinants of tumour response to radio-
therapy (Fertil and Malaise, 1985). It has been shown, especially
for cervical carcinomas, that intrinsic radiosensitivity measured as
surviving fraction of clonogens at 2 Gy (SF2) strongly correlated
with clinical outcome, and both local control and patient survival
(West et al, 1992, 1993, 1997). Also initial slopes of survival
curves (a values) for cervix carcinoma and head and neck cancer
were significantly correlated with local control and overall
survival (Girinsky et al, 1992). A similar trend, although insignifi-
cant, was also observed by the same authors for SF2.
Radiotherapy is a method of choice in advanced stages of cervix
cancer, also at our Centre. However, local recurrences are often the
reason of treatment failure. Since a great inter-tumour hetero-
geneity in radiosensitivity has been observed even within one
histological type of cervical tumour, e.g. SF2 = 0.47 (coeffi-
cient of variation, cv = 38%) for squamous cell carcinoma and
SF2 = 0.59 (cv = 46%) for adenocarcinoma (Davidson et al, 1990),
one can expect that this heterogeneity contributes to difference in
clinical response. Therefore, the ability to select patients with a
high probability of recurrence on the basis of cellular radiosensi-
tivity would be useful in deciding about adjuvant treatment.
The clonogenic or population growth assays are most frequently
used for evaluation of cellular radiosensitivity. They are, however,
rather laborious and long-lasting methods, not suitable for routine
application. Therefore, some quicker alternative clinically useful
methods are required. Different non-clonogenic assays of DNA
damages are currently tested as alternatives. Among them,
becoming popular and promising are methods measuring DNA
double-strand breaks induction and rejoining (Schwartz
et al, 1991, 1996; Whitaker et al, 1995), as well as cytogenetic
assay of micronuclei (MN), (Shibamoto et al, 1991, 1994, 1998;
Bakker et al, 1993; Zölzer et al, 1995). The micronucleus assay
elicited much interest due to its relative simplicity and rapidity in
comparison with clonogenic survival assay. Since micronuclei
arise from disturbed genetic materials such as acentric chromo-
somal fragments (Heddle and Carrano, 1977), or even whole
chromosomes (Weissenborn and Streffer, 1991), the cells con-
taining micronuclei are potentially dead. Some experiments on
established normal cell lines (Midander and Revesz, 1980), on
human tumour xenografts (Shibamoto et al, 1991) and on early
passages of human tumour cells (Wandl et al, 1989) indicated
good correlation between radiation-induced micronucleus
frequency and clonogenic cell survival. Our own study on
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both end-points (Widel et al, in preparation). However, results of
studies by Bush and McMillan (1993), Villa et al (1994) and
Champion et al (1995) have shown some divergence between
micronucleus frequency and clonogenic cell survival. On the other
hand, Shibamoto et al (1994, 1998) found a positive correlation
between frequency of micronuclei induced in vitro in different
types of human tumours and an early clinical response to radio-
therapy. Furthermore, it has been shown by conventional micronu-
cleus assay that an increase of micronucleus frequency in head and
neck cancer during radiotherapy is related to better prognosis, in
comparison with patients whose tumours indicated no change in
micronuclei (Zamboglou et al, 1992). Similarly in cervix cancer,
increase of MN frequency during radiotherapy correlated,
although insignificantly, with better prognosis (Zölzer et al, 1995).
However, increase of MN frequency together with diminution of S
phase fraction during radiotherapy was significantly correlated
with higher 5-year survival (Zölzer et al, 1995). Thus, definite
elucidation of predictive value of micronucleus assay needs
further experimentation.
In our study we attempted to compare sensitivity of advanced
stage cervical carcinomas to induction of micronuclei after irra-
diation in vitro (2–4 Gy) and in vivo (10 ´ 2 Gy) and to analyse
correlation between these biological parameters and clinical
outcome after radiotherapy. The results from 64 patients with a
mean 2.5-year follow-up are presented.
MATERIALS AND METHODS
Patients and treatment
Sixty-four patients with stage II B–IV (FIGO) cervical tumours
were selected for study between January 1992 and November
1995. Thirteen patients had stage II B tumours, 49 had stage III B
and two had stage IV B with para-aortic lymph node involvement.
All tumours were squamous cell carcinomas. The mean age of
patients was 47.8 with a range 33–71 years. Mean haemoglobin
(Hb) level prior to radiotherapy was 12.9 g dl–1 (8 M l–1) with a
range 8.4–16.5 g dl–1 and patients were transfused if the Hb level
was lower than 10 g dl–1 before radiotherapy, or if it dropped
below this level during the treatment.
All patients were treated by radiotherapy. According to the
scheme accepted in our Centre, the treatment starts from external
beam irradiation (Co-60 g-rays, or 9 or 21 MV fotons) to the whole
pelvis without shielding using 2 Gy per fraction (2 ´ 1 Gy) given
through opposed anterior-posterior fields. After 30 Gy a central
shielding was used to protect bladder and rectum. External irradia-
tion up to 48–52 Gy (increasing dose in more advanced disease)
was followed by intracavitary HDR-afterloading brachytherapy
with Ir-192. Eight to nine fraction of 5 Gy calculated to the Point
A were given at 3-day intervals. Total dose from brachytherapy
was 40–45 Gy to point A.
Tumour biopsies were taken before starting the radiotherapy
and after 20 Gy (10 fraction of 2 Gy from external irradiation).
The follow-up schedule applied in our Centre was 1 month after
finishing the treatment and every 2 months during the first year,
followed by 3-monthly controls in the second year and 6-monthly
controls in subsequent years. The study was approved by local
Medical Ethical Committee and all patients gave informed consent
before entry.
Tumour processing and micronucleus assay in vitro
Tumour biopsies for cytokinesis-block micronucleus assay
(CBMN-assay) in vitro were obtained a few hours before begin-
ning the radiotherapy. The methods of tumour processing in order
to obtain single-cell suspension for cell culture were presented
elsewhere (Widel et al, 1997). Briefly, tumour specimens (50–
200 mg) were washed twice in antibiotic-rich medium and minced
with scissors. A small part of minced tissue (10–20 mg) was used
for assessment of spontaneous micronucleation before radio-
therapy (see the next paragraph). The rest was digested in
collagenase/dispase (Boehringer-Mannheim, Germany; 0.5 mg
ml–1 in physiological saline) for 30 min at 37°C. Cells were
filtered through a stainless mesh (50 mm), spun down and re-
suspended in growth medium (GM). The GM was Dulbecco’s
modified medium and Ham’s nutrient mixture F12 (Sigma,
Germany) enriched with 20% of fetal bovine serum (FBS; Gibco,
UK), hormones (5 mg ml–1 insulin, 5 mg ml–1 hydrocortisone, both
from Sigma) and 5 ng ml–1 epidermal growth factor, 10 mg ml–1
transferrin and 1 mg ml–1 fibronectin (all from Boehringer-
Mannheim, Germany). Three millilitres of cell suspension at
concentration 1–2 ´ 105 viable cells per 1 ml (viability examined
by trypan blue exclusion) were plated per dish in a series of nine
dishes (Nunc, 25 cm2) and incubated for attachment and
spreading. Usually after 24 h incubation, well-attached and spread
cells were irradiated with 2 and 4 Gy (Co-60 g-rays, dose rate 1 Gy
min–1, room temperature). Non-irradiated control dishes were
sham exposed at the same time to keep changes in pH and temper-
ature similar. Immediately after irradiation medium was removed
and 5 ml of fresh GM containing cytochalasin B (2 mg ml–1;
Sigma, USA) was added. Incubation was terminated at 96 h after
irradiation and cells were fixed in situ with glutaraldehyde and
stained with Schiffs’ reagent, as presented elsewhere (Shibamoto
et al, 1991; Widel et al, 1997). Micronuclei were scored in binu-
cleated cells under Zeiss-Opton microscope (1000 ´ magnifica-
tion) using bright field or/and phase contrast equipment. Tumour
cells were differentiated with normal fibroblasts on the basis of
squamocellular appearance and morphological features character-
istic for tumour cells, such as: high ratio of nucleus/cytoplasm
volume, irregularity in nucleus shape and in density of staining
(Shibamoto et al, 1994, 1998). At least 100 binucleated cells
(BNC) were scored per dish. Since binucleation frequency was
rather low in this tumour type, it was necessary to score a total
number of 500–1000 cells; however, in few cases it was not even
possible to find 100 BNC per 1000 cells. Three dishes were used
per treatment dose. The BNC with one or more micronuclei were
counted and frequency of binucleated cells with micronuclei (%
BNC with MN) as well as number of micronuclei per binucleated
cell (MN/BNC) were calculated.
Micronucleus assay in vivo
To evaluate the incidence of micronuclei after irradiation in vivo,
the tested dose of 20 Gy given to the tumour (10 daily fractions of
2 Gy from external source) was chosen. For this assay biopsies
were taken two times, first before radiotherapy (the same biopsy as
for MN assay in vitro) and again after 20 Gy. Second biopsies
were taken approximately after 24 (±1) h after 10th fraction of
2 Gy. In both cases tumour tissue was minced with scissors
and pressed with tweezers through a nylon 50-mm mesh while
rinsing with phosphate-buffered saline. Cells were spun down,
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MN-analysis, cells were refixed in acetic acid:methanol 1:3 (v/v)
and microscopic slides were prepared. After being air-dried
overnight, slides were stained according to standard Pappenheim
procedure with May–Grünwald Giemsa stain (POCH, Gliwice,
Poland). This method of staining was preferred to fluorescent dyes
used by others in somewhat similar studies (Zölzer et al, 1995)
since it allows differentiation between tumour and non-tumour
cells (infiltrating lymphocytes, granulocytes and macrophages).
Micronuclei were scored at least in 1000 tumour cells and
expressed as number of micronuclei per cell. Spontaneous level of
micronuclei before radiotherapy (MNSP) was considered as 100%
and level of micronuclei after 20 Gy (MN20) was considered as
relative increment for particular tumour and was calculated
according to the equation:
Statistical analysis
Local control was evaluated from the date of finishing the
brachytherapy to the date of appearance of recurrence. Survival
was measured from the date of finishing the brachytherapy to the
date of last follow-up or death. Estimates of cumulative proportion
of recurrences and overall survival were done by the
Kaplan–Meier method using Statistica v.5.0 software. The differ-
ences between particular arms presented in the Figures were
analysed for significance using the log-rank test. The differences
between data sets for patients who died and those who were alive
at the time of analysis were analysed using Student’s t-test for
significance (Table 1).
RESULTS
Six patients of 64 selected for the study did not complete radio-
therapy because of tumour progression and/or complications
caused by advanced disease. Data from all 58 patients who
completed full course of radiotherapy were included in the
Kaplan–Meier analysis of survival and local control probability.
Two of them with locally controlled tumours and in good general
status were lost after 19 and 22 months of observation. The rest
had a minimum 2.5-year post-treatment follow-up (range 28–66
months). All patients were included in analysis of age, haemo-
globin level and some biological data presented in Table 1. The
frequency of micronuclei was evaluated after irradiation of tumour
in primary culture (2 and 4 Gy) and in vivo using 20 Gy as a tested
dose. It was possible to evaluate micronucleus frequency after
2 Gy in vitro in 43/64 tumours (67%), where cell cultures were
successful. Because of insufficient amount of cells isolated from
biopsies, data at 4 Gy were obtained for 35 tumours only. The
main data obtained from in vitro assay are summarized in Table 2.
We observed great variation in binucleation yield in non-irradiated
control cells as well as in irradiated ones. The mean percentage of
BNC at 0 Gy was 15.8% (range 7.0–45.0) indicating that dividing
fraction in this tumour type is rather low. Despite a long time of
incubation with cytochalasin B (96 h chosen in preliminary study
as optimal), the yield of multinucleated cells was negligible
(0–3%, data not presented). The average yield of BNC dropped to
12.52 and 10.91% at 2 Gy and 4 Gy, respectively, due to inhibition
of cell cycle progression. The micronucleus frequency expressed
as either % BNC with MN or MN/BNC increased with increasing
dose (Table 2). The very weak correlation was found between
% BNC and frequency of BNC with MN at 2 Gy (r = 0.169) and 4
Gy (r = 0.219). Corresponding correlation coefficients for % BNC
vs MN/BNC were 0.367 at 2 Gy and 0.220 at 4 Gy. Since data at
Micronucleus assay in cervix cancer 1601
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MN/cell after 20 Gy
MN20 (%) = ´ 100
MN/cell before RT 
Table 1 Comparison of some biological and clinical data between the groups of patients who died and those who are alive at the time of analysis
Parameter evaluated Group of patients Significancea
Dead Alive
Total number of patients 29 35
FIGO stage: II B 1 12
III B 28 21
IV B 0 2
Age of patientsb 48.2 ± 9.5 47.4 ± 8.4 P = 0.7
Haemoglobin level at the start 12.6 ± 1.9 13.4 ± 1.5 P = 0.1
of treatment (g/dl)b
% BNC at 0 Gyb 17.5 ± 10.25 14.39 ± 3.39 P > 0.2
(n = 20) (n = 23)
% BNC with MN at 2 Gyb,c 17.76 ± 5.43 16.42 ± 5.16 P = 0.4
(n = 20) (n = 23)
MN/BNC at 2 Gy in vitrob,c 0.234 ± 0.07 0.216 ± 0.06 P = 0.4
(n = 20) (n = 23)
Spontaneous micronucleus
frequency before radiotherapy 3.28 ± 1.3 (´10–2) 2.74 ± 1.2 (´10–2) P = 0.1
(MNSP)b (n = 29) (n = 35)
Percent increment of
micronucleus frequency after 20 174.04 ± 83.93 207.1 ± 110.22 P = 0.2
Gy in vivo in relation to MNSP (n = 27) (n = 34)
(MN20)b
Survival timeb after radiotherapy 15.89 ± 10.20 42.45 ± 11.42 P < 0.001
(months)
aStudent’s t-test; bmean ± s.d.; ccorrected for 0 Gy data.1602 M Widel et al
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Table 2 The main results of cytokinesis-block micronucleus assay in primary culture of cervical carcinomas
Parameter Dose (Gy)
02 42 a 4a
% BNC Mean 15.84 12.52 10.91
± s.d. 8.50 5.10 4.44
Range 7.00–45.00 6.0–33.00 6.00–28.00
cv (%) 54 41 41
n 43 43 34
% BNC with MN Mean 8.50 25.35 32.90 17.04 24.20
± s.d. 4.90 6.08 10.42 5.27 8.53
Range 0.00–17.00 13.00–41.00 14.00–66.00 9.00–30.00 10.00–50.00
cv (%) 57 24 32 31 35
n 43 43 34 43 34
MN/BNC Mean 0.096 0.315 0.415 0.224 0.321
± s.d. 0.062 0.090 0.132 0.066 0.116
Range 0.00–0.257 0.160–0.626 0.180–0.683 0.080–0.416 0.109–0.584
cv (%) 65 29 32 30 36
n 43 43 34 43 34
s.d., standard deviation; cv, coefficient of variation, aafter correction for 0 Gy data.
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Figure 1 Cumulative frequency distribution of the percentage of
binucleated cells with micronuclei (A) and number of micronuclei per
binucleated cells (B) estimated in vitro for 43 advanced stage cervical
carcinomas. Local recurrences and distant metastases are indicated by
arrows and dots respectively
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Figure 2 Local control (A) and overall survival (B) probability vs.
micronucleus frequency at 2 Gy (after correction for 0 Gy) estimated in vitro.
The data for patients who completed full course of radiotherapy are divided
into two groups for those below and above or equal to the median value of
MN/BNC4 Gy were obtained for 34 tumours only (53%) they were not
further analysed and considered as not representative for the whole
group. Figure 1 shows the cumulative frequency distribution of
% BNC with MN and MN/BNC at 2 Gy. Both plots indicate very
similar shape and normal distribution of values. The local recur-
rences and metastases that are indicated by arrows and dots respec-
tively, are almost equally distributed below and over the median
values in each plot. However, these indicators of metastases and
recurrences are not ideally placed in the same spots of both plots
since there is no ideal correlation between % BNC with MN and
MN/BNC (r = 0.710, Table 3). The MN/BNC at 2 Gy was further
used for analysis of correlation between clinical outcome and
radiation sensitivity of tumour cells. Figure 2 presents the relation-
ships between tumour local control or patient overall survival and
MN/BNC at 2 Gy corrected for 0 Gy. The results from patients
who completed full course of radiotherapy were divided according
to the median (equal 0.220). Although tumour local control proba-
bility at 58th month was almost 20% higher for the group with
MN/BNC over the median, significance has not been achieved
(Figure 2A). Furthermore, there were no differences in overall
survival between both arms (Figure 2B). If we split the data into
four quartiles, we could not find any correlation with clinical
outcome either (data not presented). Also average binucleation
frequency which indirectly reflects proliferative activity of
tumours did not influence clinical results and was only slightly
higher in the group of patients who died than in the group of
patients who were alive at the time of analysis (Table 1). On the
basis of data obtained for 40 patients who completed the  full
course of radiotherapy we can state that micronucleus assay in
vitro will have limited usefulness for predicting treatment outcome
at least for patients with cervical carcinomas.
The micronucleus frequency after 20 Gy in vivo (MN20) was
estimated for 61 tumours and was expressed as the per cent
increment in relation to spontaneous micronucleus frequency
(MNSP). Spontaneous micronucleus frequency was estimated in
all 64 tumours. Median value for MNSP was 2.8 ´ 10–2 per cell
(range 0.16–6.8 ´ 10–2 per cell). We observed that better prognosis
was connected with the moderate values of MNSP, as presented in
Figure 3, where local control and overall survival were analysed in
relation to MNSP stratified according to four quartiles. It can be
seen that patients with either extremely high or low values of
MNSP mostly belonged to the group with shorter time of loco-
regional control (Figure 3A). Significant difference in local control
probability (P = 0.049) was achieved only between arms repre-
senting moderate value (1.9 ≤ MNSP <2.8 ´ 10–2 per cell) and
arms representing MNSP ³3.8  ´ 10–2 per cell (Figure 3A).
Survival of patients was also considerably lower for the group with
MNSP above the fourth quartile (Figure 3B). However, precise
analysis of the data for tumours represented by the lowest arm in
Figure 3 has revealed that nine of 15 tumours with MNSP above
the fourth quartile (MNSP > 3.8 ´ 10–2 per cell) simultaneously
showed the low increase of micronucleus number after 20 Gy,
lower than median value for this parameter set, and six of these
tumours had MN20 below first quartile value. Nevertheless, very
low correlation was observed in general between MNSP and
MN20 (r = 0.290) for 58 tumours (Table 3). Data presented in
Figures 4–6 indicate that increment of micronucleus frequency in
vivo after 20 Gy dose (MN20) may have predictive value for treat-
ment outcome. Figure 4 presents the local control (Figure 4A) and
overall survival probability (Figure 4B) in relation to MN20 strati-
fied according to the median value (163.5%). Data combine all
stage patients who completed full course of radiotherapy. A
significantly higher (P = 0.009), at least 3-year, local control was
Micronucleus assay in cervix cancer 1603
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Table 3 Correlation between some data of micronucleus assay in vitro and
in vivo
Correlation between parameters Correlation Number of
coefficient tumours/
(r) evaluated
% BNC (2 Gy) and % BNC with MN (2 Gy)a 0.169 43
% BNC (2 Gy) and MN/BNC (2 Gy)a 0.367 43
% BNC with MN (2 Gy)* and MN/BNC (2 Gy)a 0.710 43
% BNC (4 Gy) and % BNC with MN (4 Gy)a 0.219 34
% BNC (4 Gy) and MN/BNC (4 Gy)a 0.220 34
MN/BNC (0 Gy) and MN/BNC (2 Gy) 0.660 43
MN/BNC (0 Gy) and MNSP 0.176 43
MN/BNC (2 Gy)a and MN20 0.324 41
MNSP and MN20 0.290 58
a Corrected for 0 Gy data.
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Figure 3 Local control (A) and overall survival (B) probability vs. frequency
of spontaneous micronuclei per cell. The data for patients who completed full
course of radiotherapy are stratified according to the four quartiles of MNSP
(the values of micronuclei per cell given in the frame should be multiplied by
10–2). Significant differences were obtained only for two arms signed by # in
A; the differences between others were not significantachieved for the group of patients whose tumours responded by
higher increment of micronucleus frequency (MN20 above the
median, upper arm in Figure 4A) than for the group whose
tumours showed MN20 below the median (lower arm in Figure
4A). Only one tumour in superior arm progressed despite the
radiation treatment and three others recurred within the first year
after radiotherapy. In the group of patients with MN20 lower than
the median, six tumours progressed or stagnated in spite of radia-
tion treatment and seven others recurred within 2 years (lower arm
in Figure 4A). The significance was not achieved for overall
survival (Figure 4B) probably because of generally shorter follow-
up time for patients who belonged to the group with MN20 over
the median. The similar trend was also observed for a narrower
group of patients with stage III–IV of disease which included
42 patients in stage III B and two in stage IV (data not shown).
Significance was obtained for local control (P = 0.019) but not for
overall survival probability (P = 0.29).
Figure 5 clearly indicates that higher local control can be
achieved when tumours respond to irradiation by high increase of
micronucleation during radiotherapy (MN20 ³ 163.5%, arm c,
Figure 5A). High significant difference (P = 0.003) between this
group and group of tumours with MN20 below first quartile
(MN20 < 117.5%; arm a) was noticed. At least a 3-year local
control was observed in 86% of patients in arm c representing
MN20 over the median and only in about 42% in arm a (MN20
below first quartile). Significance was also achieved (P = 0.04) for
both arms when overall survival was analysed.
Another analysis restricted to III B and IV stage (Figure 6)
brings further clear evidence that lack of change, or only small
increase of micronucleus frequency during the first course of
radiotherapy, is an unfavourable prognosticator for tumour local
control and total survival of patients. The 3-year local control was
approximately 40% lower in the group with MN20 below 117.5%
(P < 0.007) and total survival was lower by almost 30%
(P < 0.041). Very similar relationships were obtained for the whole
group II B–IV (data not illustrated), with significance at P < 0.008
and P < 0.045 for local control and total survival respectively.
Although these data are not presented, it should be mentioned that
increase of micronucleus frequency in vivo (MN20) was indepen-
dent of patient’s age (r = –0.112) and of haemoglobin level
(r = –0.123). It is also seen from Table 2 that clinical parameters
such as age and haemoglobin level had no influence on patient
survival.
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Figure 4 Local control (A) and overall survival (B) probability vs increment
of micronucleus frequency after 20 Gy in vivo in patients with stage II B–IV
cervical carcinoma who completed full course of radiotherapy. The data are
stratified according to the median value for MN20 equal to 163.5% of
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Figure 5 Local control (A) and overall survival (B) probability vs increment
of micronucleus frequency after 20 Gy in vivo for stage II B–IV tumours. The
upper arm represents tumours with MN20 above the median; middle arm
represents MN20 between the median and first quartile and lower arm
represents MN20 below the first quartile
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MN20 < 117.5
b (n = 14)
a (n = 14)
117.5 £ MN20 < 163.5
MN20 ù 163.5
a vs b, P = 0.17
b vs c, P = 0.12
a vs c, P = 0.003
c (n = 28)
MN20 < 117.5
b (n = 14)
a (n = 14)
117.5 £ MN20 < 163.5
MN20 ù 163.5
a vs b, P = 0.20
b vs c, P = 0.74
a vs c, P = 0.04DISCUSSION
The data presented by West et al (1993, 1997) clearly indicate that
intrinsic radiosensitivity of cervical carcinomas measured as
surviving fraction at 2 Gy in soft agar clonogenic assay can be
used in predicting the outcome of patient treated by radiotherapy.
However, methods based on cell survival are clinically not particu-
larly applicable, mostly because of the long time (few weeks)
needed to obtain final results. In our study we applied the cyto-
kinesis-block micronucleus test as a possible alternative assay of
tumour radiosensitivity in vitro. We also wanted to estimate simul-
taneously the frequency of micronuclei in tumour cells when
radiation was administered to the tumour in situ. Usefulness of
micronucleus assay for prediction of cellular radiosensitivity has
not been definitively established yet. Reports about correlation
between micronucleus frequency and reproductive cell death are
controversial. A good correlation between clonogenic cell survival
and micronucleus frequency in tumour cell lines was presented by
several investigators (Wandl et al, 1989; Stap and Aten, 1990;
Bakker et al, 1993). However, other studies brought contrasting
results (Bush and McMillan, 1993; Slavotinek et al, 1993; Villa
et al, 1994; Champion et al, 1995), indicating that lethal events
measured as surviving fraction not always coincide with MN
frequency. Unfortunately, micronucleus assay was always used to
compare radiation sensitivity of established cell lines or primary
culture of tumours of widely differing origin. The recent paper of
Mariya et al (1997) based on the three murine tumour cell lines of
the same origin but of different radiosensitivity evidenced strong
correlation between frequency of micronuclei and clonogenic
survival. Therefore, it seems that in order to evaluate the useful-
ness of micronucleus test as a predictive assay of radiosensitivity
for clinical aims, only one tumour type should be used in a study.
Our earlier report on a smaller group of patients (Widel et al, 1993)
showed that both micronucleus frequency estimated in primary
culture at clinically relevant doses 2–4 Gy, as well as micronucleus
incidence induced by tumour irradiation in situ (10 ´ 2 Gy),
widely differed among the tumours evaluated. The present paper
comprises study results from 64 patients.
The prerequisite for successfully applying the cytokinesis-block
micronucleus test to tumour cells isolated directly from biopsies
was to obtain satisfactory cell outgrowth directly on plastic dishes.
The success rate was 67%, which is roughly comparable to the
71% success rate for SF2 measured by West et al (1997) in soft
agar colony assay. The radiation sensitivity at 2 Gy expressed as
number of micronuclei per binucleated cell (MN/BNC) ranged
from 0.08 to 0.416 (mean 0.224 ± 0.065). Number of MN/BNC
was insignificantly lower (P = 0.3) in stage II B tumours (0.199 ±
0.098) than in more advanced stages III–IV (0.231 ± 0.065) (data
not presented). However, data were obtained for nine tumours in
stage II B in comparison with 34 tumours in stage III–IV.
Therefore, all data were used for correlation analysis between
micronucleus frequency in vitro and clinical outcome. Although
local control is slightly higher for tumours showing a higher
number of MN/BNC, the difference is not significant (Figure 2A).
There is no difference in overall survival of patients in relation to
micronucleus frequency measured at 2 Gy in vitro. This is also
confirmed by data presented in Table 2, where mean value of
MN/BNC is even slightly higher for patients who died than that for
those who were alive at the time of analysis.
Our results can not be directly compared with literature data.
The only data evaluating correlation between response to radio-
therapy of different human tumours with micronucleus frequency
measured in primary culture as MN/BNC at 2 Gy indicate that
such correlation exists (Shibamoto et al, 1994). However, this
correlation concerns only early response to radiotherapy and is not
precisely determined. It was also demonstrated (Shibamoto et al,
1998) that proliferative activity expressed as dividing fraction
(DF) of tumour cells estimated on the basis of BNC plus multi-
nucleated cells in CBMN assay highly correlated with relapse-free
survival of patients with non-small-cell lung cancer. High DF was
an unfavourable prognosticator. Although we have not performed
similar comparison, the dividing fraction in cervix cancer seems to
be low since we seldom observed multinucleated cells (0–3%) and
average percentage of BNC was 15.84% in non-irradiated control.
Low proliferative activity might be the reason that all damaged
cells were not able to express micronuclei and thus estimated
MN/BNC did not correlate with tumour responsiveness.
Furthermore, in some samples the number of BNC counted per
dish was even below 100. This is probably a common problem
associated with CBMN assay on primary cultures of tumour cells,
since in the study of Shibamoto et al (1998) only 50 BNC were
scored per some dishes. In our study, correlation between binucle-
ation yield and micronucleus frequency (MN/BNC at 2 Gy) is low
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Figure 6 Local control (A) and overall survival (B) probability vs increment
of micronucleus frequency after 20 Gy in vivo for patients with stage III B–IV
only. The upper arms in both panels represent MN20 over the first quartile
and lower arms are for MN20 below first quartile(r = 0.367), but it is in good agreement with the recent data
presented by Johansen et al (1998) for human fibroblasts.
Interestingly, these authors have not observed a correlation
between either % BNC with MN (at 2 and 3.5 Gy) or clinical
radiosensitivity assessed by excess risk of fibrosis.
In our study, binucleation percentage was comparable between
the group of patients who died and the group who were alive at the
time of analysis (Table 2), indicating that this parameter is also of
minor importance for patient survival. The lack of correlation
between cellular radiosensitivity estimated in CBMN assay and
clinical outcome can probably be also ascribed partly to some
selection of tumour cells during adaptation to artificial culture
conditions. We observed that part of plated cells did not attach to
the bottom of culture dishes and these cells were lost for the
measurement of micronuclei. This problem is avoided in MN-
assay after irradiation in vivo. Tumour biopsy after irradiation is
mechanically disaggregated and cell suspension obtained contains
all released cells. Thus it represents a larger population of tumour
cells than the primary culture. The lack of correlation between
spontaneous micronucleus frequency in vivo (MNSP) and in vitro
(MN/BNC at 0 Gy), (Table 3) might support this supposition. Very
low correlation was observed between MN/BNC at 2 Gy and
MN20 in vivo (r = 0.324, Table 3). Although the index of radiation
sensitivity in vitro does not correlate with clinical results, the
increment of micronucleus frequency in vivo does. The micro-
nucleus assay in vivo does not measure the intrinsic radiosensi-
tivity separately, but overall radiation-induced cell damage that is
influenced by environmental factors such as hypoxia, cellular
proliferation, cell to cell contact and other host-related factors.
Furthermore, MN20 reflects cytogenetic damage after fractionated
irradiation, contrary to MN/BNC in vitro, estimated at single dose
of 2 Gy. Although one can claim that MN20 measured in vivo is a
rather crude parameter, it seems nevertheless useful for prediction
of tumour response. A somewhat similar study was also performed
on cervical cancer by Zölzer et al (1995). These authors observed
that patients whose micronucleus frequency increased during
radiotherapy together with diminution of S phase fraction had
significantly better prognosis (5-year survival), although no single
parameter evaluated could be judged statistically significant, prob-
ably because of insufficient number of patients included in this
study.
Micronucleus increment after 20 Gy in our study seems to be a
better predictor of local control than patient survival. When we
analysed the causes of death in the group of patients with MN20
lower than median (<163.5% of pretreatment value), it appeared
that 87% of patients died because of local recurrences and 13%
died because of distant metastases. In the group of patients with
MN20 >163.5% of pretreatment value, 40% of deaths were caused
by recurrences and 60% by metastases and/or general health
complications. In the group of patients with very low increment of
MN20, below the first quartile (Figures 5 and 6), the cause of
death was mainly a progression of disease (89%). These results
mean that the higher increase in micronucleus frequency, the
greater is the cell killing, and consequently greater is tumour
response. Therefore, we can state that lack of change or only slight
increase of MN frequency after 20 Gy in comparison with sponta-
neous MN frequency before radiotherapy strongly suggests that
tumour probably will not be cured by radiotherapy alone and adju-
vant treatment, e.g. chemotherapy should be considered after
radiotherapy. In such a way, the increment of micronucleus
frequency in vivo can offer a potentially valuable approach to
predicting individual radiosensitivity and may also be of assis-
tance in individualizing treatment strategy to improve cure rate in
advanced stages of cervix cancer.
ACKNOWLEDGEMENTS
This work has been conducted as the project No 2.5, Theme 3 S for
1997 within the Central Scientific Project of the Centre of
Oncology.
REFERENCES
Bakker PJM, Tukker LJ, Stap J, Veenhof CHN and Aten JA (1993) Micronuclei
expression in tumours as a test for radiation sensitivity. Radiother Oncol 26:
69–72
Bush C and McMillan TJ (1993) Micronucleus formation in human tumour cells:
lack of correlation with radiosensitivity. Br J Cancer 67: 102–106
Champion AR, Hanson JA, Court JB and Venables SE (1995) The micronucleus
assay: an evaluation of its use in determining radiosensitivity in vitro.
Mutagenesis 10: 203–208
Davidson SE, West CML, Roberts SA, Hendry JH and Hunter RD (1990)
Radiosensitivity testing of primary cervical carcinoma; evaluation of intra- and
inter-tumour heterogeneity. Radiother Oncol 18: 349–359
Fertil B and Malaise EP (1985) Intrinsic radiosensitivity of human cell lines is
correlated with radioresponsiveness of human tumors. Analysis of 101
published survival curves. Int J Radiat Oncol Biol Phys 11: 1699–1707
Girynsky T, Lubin R, Pignon JP, Chavaudra N, Gazean J, Dubray B, Cosset JM,
Socie G and Fertil B (1992) Predictive value of in vitro radiosensitivity
parameters in head and neck cancers and cervical carcinomas: preliminary
correlations with local control and overall survival. Int J Radiat Oncol Biol
Phys 25: 3–7
Heddle JA and Carrano AV (1977) The DNA content in micronuclei induced in
mouse bone marrow by gamma irradiation: evidence that micronuclei arise
from acentric chromosomal fragments. Mutat Res 44: 63–69
Johansen J, Streffer C, Fuhrmann C, Bentzen SM, Stausbøl-Grøn B, Overgaard M
and Overgaard J (1998) Radiosensitivity of normal fibroblasts from breast
cancer patients assessed by the micronucleus and colony assays. Int J Radiat
Biol 73: 671–678
Mariya Y, Streffer C, Fuhrmann C and Wojcik A (1997) Correlation of radiation-
induced micronucleus frequency with clonogenic survival in cells of one
diploid and two tetraploid murine tumor cell lines of the same origin. Radiat
Res 147: 29–34
Midander J and Revesz L (1980) The frequency of micronuclei as a measure of cell
survival in irradiated cell populations. Int J Radiat Biol 38: 237–242
Schwartz JL, Mustafi R, Beckett MA, Czyz ·ewski EA, Farhangi E, Grdina DJ,
Rotmensch R and Weichselbaum RR (1991) Radiation-induced DNA double-
strand break frequencies in human squamous cell lines of different radiation
sensitivities. Int J Radiat Biol 59: 1341–1352
Schwartz JL, Mustafi R, Beckett MA and Weichselbaum RR (1996) DNA double-
strand break rejoining rates, inherent radiation sensitivity and human tumour
response to radiotherapy. Br J Cancer 74: 37–42
Shibamoto Y, Streffer C, Fuhrmann C and Budach V (1991) Tumor radiosensitivity
prediction by the cytokinesis-block micronucleus assay. Radiat Res 128:
293–300
Shibamoto Y, Shibata T, Miyatake S, Oda Y, Manabe T, Ohshio G, Yagi K, Streffer
C, Takahashi M and Abe M (1994) Assessment of the proliferative activity of
human tumours using the cytokinesis-block micronucleus assay. Br J Cancer
70: 67–71
Shibamoto Y, Ike O, Shibata T, Takahashi M, Abe M and Streffer C (1998) The
cytokinesis-block micronucleus assay for the prediction of proliferative activity
and radiosensitivity of human tumors. In: Progress in Radio-Oncology VI,
Kogelnik HD and Sedlmayer F (eds), pp. 509–515. Munduzzi Editore:
Bologna, Italy
Slavotinek A, McMillan TJ and Steel CM (1993) A comparison of micronucleus
frequency and radiation survival in lymphoblastoid cell lines. Mutagenesis 8:
569–575
Stap J and Aten JA (1990) Comparison of radiation sensitivity for three cell lines as
measured by the cloning assay and the micro-nucleus test. Strahlenther Onkol
166: 761–763
Villa R, Zaffaroni N, Gornati D, Costa A and Silvestrini R (1994) Lack of
correlation between micronucleus formation and radiosensitivity in established
and primary cultures of human tumours. Br J Cancer 70: 1112–1117
1606 M Widel et al
British Journal of Cancer (1999) 80(10), 1599–1607 © 1999 Cancer Research CampaignWandl EO, Ono K, Kain R, Herbsthofer T, Heinert G and Hobarth K (1989) Linear
correlation between surviving fraction and the micronucleus frequency. Int J
Radiat Biol 56: 771–775
Weissenborn U and Streffer C (1991) Micronuclei with kinetochores in human
melanoma cells and rectal carcinomas. Int J Radiat Biol 59: 373–383
West CML and Hendry JH (1992) Intrinsic radiosensitivity as a predictor of patient
response to radiotherapy. Br J Radiol 24: 146–152
West CML, Davidson SE, Roberts SA and Hunter RD (1993) Intrinsic
radiosensitivity and prediction of patient response to radiotherapy for
carcinoma of the cervix. Br J Cancer 68: 819–823
West CML, Davidson SE, Roberts SA and Hunter RD (1997) The independence of
intrinsic radiosensitivity as a prognostic factor for patient response to
radiotherapy of carcinoma of the cervix. Br J Cancer 76: 1184–1190
Whitaker SJ, Ung YC and McMillan TJ (1995) DNA double-strand break induction
and rejoining as determinants of human tumour cell radiosensitivity. A
pulsed-field gel electrophoresis study. Int J Radiat Biol 67: 7–18
Widel M, Dobrut M, Maka B, Lubecka B, Pluciennik A (1997) The radiosensitivity
of human malignant melanomas evaluated by cytokinesis-block micronucleus
assay. Neoplasma 44: 109–116
Widel M, Konopacka M, Jedrus S and Owczarek S (1993) Evaluation of the human
cervical carcinoma cells radiosensitivity by the micronucleus assay. Abstracts
from Annual Meeting of ESRB, Stockholm, Sweden
Zamboglou N, Streffer C, Fritzmeir CU, Bojar H, Karstens JH, Schnabel T, Kolotas
C and Schmitt G (1992) Klinische Prognose Faktoren der Radioresistenz by
Kopf-Hals-Karzinomen. Dtsch Z Mund Kiefer Gesichts Chir 16: 82–85
Zölzer F, Alberti W, Pelzer T, Lamberti G, Hulskamp FH and Streffer C (1995)
Changes in S phase fraction and micronucleus frequency as prognostic factor in
radiotherapy of cervical carcinoma. Radiother Oncol 36: 128–132
Micronucleus assay in cervix cancer 1607
British Journal of Cancer (1999) 80(10), 1599–1607 © 1999 Cancer Research Campaign